{
  "schemaVersion": 1,
  "generated": "2026-08-22",
  "purpose": "Public change log for meaningful MedicineCostHelp catalog, coverage, coding and policy updates. Entries summarize human-reviewed public changes; they are not patient records.",
  "entries": [
    {
      "date": "2026-08-22",
      "type": "platform-update",
      "title": "SEO control system and IndexNow architecture launched",
      "summary": "Added automated sitemap grouping, canonical and orphan-page regression checks, explicit legacy clean-URL redirects, and changed-URL IndexNow notification for participating search engines.",
      "url": "/sources-methodology.html",
      "source": "https://medicinecosthelp.com/sources-methodology.html"
    },
    {
      "date": "2026-08-22",
      "type": "trust-update",
      "title": "Source methodology and medication cost-context standard published",
      "summary": "Published the source hierarchy, human-review model, editorial and correction standards, accessibility target, and a clear rule against presenting false-precision patient medication prices.",
      "url": "/what-will-my-expensive-medicine-cost.html",
      "source": "https://medicinecosthelp.com/what-will-my-expensive-medicine-cost.html"
    },
    {
      "date": "2026-08-22",
      "type": "platform-update",
      "title": "Coverage Action Plan 2.0 launched",
      "summary": "Expanded the privacy-first action plan with Medicaid state routing, patient/caregiver versus care-team mode, questions to ask, items to gather, and a copyable/printable handoff.",
      "url": "/coverage-roadmap.html",
      "source": "https://medicinecosthelp.com/coverage-roadmap.html"
    },
    {
      "date": "2026-08-22",
      "type": "distribution-update",
      "title": "Free patient handoff toolkit launched",
      "summary": "Added a printable QR handout and copyable patient introduction so clinics, pharmacies, hospitals and advocacy groups can share MedicineCostHelp without sending patient data.",
      "url": "/share-medicinecosthelp.html",
      "source": "https://medicinecosthelp.com/share-medicinecosthelp.html"
    },
    {
      "date": "2026-08-22",
      "type": "new-medicine",
      "title": "Trutakna added",
      "summary": "Added a selected specialty-therapy access guide for the 2026 FDA-approved atacicept-vymj subcutaneous biologic for primary IgA nephropathy.",
      "url": "/trutakna-cost-help.html",
      "source": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761486Orig1s000lbl.pdf"
    },
    {
      "date": "2026-08-22",
      "type": "new-medicine",
      "title": "Hepcludex added",
      "summary": "Added a selected specialty-therapy access guide for the first FDA-approved treatment for chronic hepatitis delta infection.",
      "url": "/hepcludex-cost-help.html",
      "source": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-hepatitis-delta-virus-hdv-infection"
    },
    {
      "date": "2026-08-22",
      "type": "new-medicine",
      "title": "Yuviwel added",
      "summary": "Added a selected specialty-therapy access guide for the 2026 once-weekly achondroplasia injection, including current manufacturer support and published payer PA pathways.",
      "url": "/yuviwel-cost-help.html",
      "source": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026"
    },
    {
      "date": "2026-08-21",
      "type": "policy-update",
      "title": "Aetna denosumab CPB 0804 reviewed",
      "summary": "Aetna added Ponlimsi to the Prolia biosimilar pathway and added site-of-care language. MedicineCostHelp updated the denosumab guidance after human review.",
      "url": "/prolia-cost-help.html",
      "source": "https://www.aetna.com/cpb/medical/data/disclaimer/review/800_899/0804_38.html"
    },
    {
      "date": "2026-08-21",
      "type": "new-medicine",
      "title": "Lytenava added",
      "summary": "Added a new-to-market coverage guide for FDA-approved ophthalmic bevacizumab-vikg for wet AMD, with payer and coding uncertainty stated explicitly.",
      "url": "/lytenava-cost-help.html",
      "source": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026"
    },
    {
      "date": "2026-08-21",
      "type": "new-biosimilar",
      "title": "Immgolis Intri added",
      "summary": "Added the interchangeable IV golimumab-sldi biosimilar to Simponi Aria and product-specific indication filtering.",
      "url": "/immgolis-intri-cost-help.html",
      "source": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilars-simponi-and-simponi-aria-golimumab-treat-rheumatoid"
    },
    {
      "date": "2026-08-21",
      "type": "label-update",
      "title": "Pluvicto expanded indication reviewed",
      "summary": "Added the July 31, 2026 FDA indication expansion for PSMA-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer in combination with ARPI therapy.",
      "url": "/pluvicto-cost-help.html",
      "source": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy"
    },
    {
      "date": "2026-08-21",
      "type": "label-update",
      "title": "Tzield 2026 indications reviewed",
      "summary": "Updated the Tzield coverage data for the 2026 Stage 2 age expansion and pediatric Stage 3 type 1 diabetes approval.",
      "url": "/tzield-cost-help.html",
      "source": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-pediatric-stage-3-type-i-diabetes"
    },
    {
      "date": "2026-08-21",
      "type": "label-update",
      "title": "Casgevy pediatric age expansion reviewed",
      "summary": "Updated the Casgevy pathway after FDA expanded eligible sickle cell disease and transfusion-dependent beta-thalassemia use to age 2 years and older.",
      "url": "/casgevy-cost-help.html",
      "source": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-young-children-sickle-cell-disease"
    }
  ]
}